HC Wainwright Has Strong Estimate for ACAD FY2027 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at HC Wainwright raised their FY2027 earnings estimates for ACADIA Pharmaceuticals in a report issued on Monday, May 19th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will earn $2.43 per share for the year, up from their previous estimate of $2.06. HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' FY2028 earnings at $2.64 EPS and FY2029 earnings at $2.78 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. The business had revenue of $244.32 million for the quarter, compared to analysts' expectations of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm's revenue was up 18.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 earnings per share.

A number of other research analysts have also weighed in on the company. Oppenheimer restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Friday, May 16th. Morgan Stanley set a $24.00 target price on ACADIA Pharmaceuticals and gave the stock an "equal weight" rating in a research note on Tuesday, May 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. BMO Capital Markets lifted their price objective on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the stock an "outperform" rating in a research report on Monday, May 19th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $26.00 price target on shares of ACADIA Pharmaceuticals in a research note on Monday, May 19th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $26.83.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD traded up $0.43 during trading hours on Wednesday, hitting $21.98. The stock had a trading volume of 1,671,707 shares, compared to its average volume of 1,933,705. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $25.23. The firm has a 50 day simple moving average of $16.38 and a 200-day simple moving average of $17.33. The firm has a market capitalization of $3.68 billion, a P/E ratio of 28.18 and a beta of 0.47.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,498 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $14.60, for a total value of $51,070.80. Following the completion of the transaction, the executive vice president now directly owns 62,773 shares of the company's stock, valued at $916,485.80. This trade represents a 5.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares in the company, valued at approximately $320,756.85. The trade was a 21.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,746 shares of company stock worth $428,221 in the last quarter. 26.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several hedge funds have recently bought and sold shares of ACAD. SG Americas Securities LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 380.3% during the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock worth $45,576,000 after acquiring an additional 1,966,607 shares during the last quarter. Barclays PLC raised its position in ACADIA Pharmaceuticals by 126.2% during the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after purchasing an additional 154,854 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $272,000. Vanguard Group Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock worth $255,939,000 after purchasing an additional 104,444 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 66.9% during the 4th quarter. Victory Capital Management Inc. now owns 162,125 shares of the biopharmaceutical company's stock valued at $2,975,000 after buying an additional 64,995 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.